Amita Datta-Mannan | Clinical Pharmacology Award | Best Researcher Award

Posted on by ScienceFather

Dr. Amita Datta-Mannan | Clinical Pharmacology | Best Researcher Award

Dr. Amita Datta-Mannan Eli Lilly & Company, United States

Amita Datta-Mannan is a seasoned pharmaceutical scientist and leader with nearly two decades of experience spanning multiple therapeutic areas. Her career has been marked by significant contributions in drug discovery and development, particularly in translational medicine and clinical pharmacology. She has held diverse roles, including leading large interdisciplinary teams and overseeing strategic initiatives to advance therapeutic modalities such as biologics, antibodies, and small molecules through various phases of clinical trials.

Publication profile

Orcid

Scopus

Education:

Amita Datta-Mannan’s academic journey includes rigorous training and education in pharmaceutical sciences. She holds advanced degrees and certifications relevant to her field, providing a solid foundation for her career in drug discovery and development. Her educational background underscores her expertise in clinical pharmacology, pharmacokinetics, and the intricate processes involved in bringing novel therapeutics from bench to bedside.

Research Focus:

Amita Datta-Mannan’s research focuses on advancing understanding in clinical pharmacology and drug metabolism. Her work spans across multiple therapeutic areas, with particular emphasis on autoimmune diseases, oncology, and rare disorders. She is passionate about integrating scientific advancements into clinical practice, aiming to improve patient outcomes through innovative therapeutic approaches.

Professional Journey:

Amita Datta-Mannan’s professional journey is characterized by progressive leadership roles in pharmaceutical research and development. She has led cross-functional teams, driving the strategy and execution of clinical trials from early-phase development to regulatory approval. Her career highlights include contributions to the design and implementation of clinical protocols, safety assessments, and pharmacological studies that have shaped therapeutic advancements in the industry.

Honors & Awards:

Throughout her career, Amita Datta-Mannan has been recognized for her contributions and achievements in pharmaceutical science. She has received prestigious honors and awards that acknowledge her leadership, innovation, and impact on advancing therapeutic modalities. These accolades underscore her dedication to excellence and her significant role in shaping the future of drug discovery and development.

Publications Noted & Contributions:

Title: Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study

Journal: Clinical Pharmacology & Therapeutics

Publication Date: May 2024

DOI: 10.1002/cpt.3185

Contributors: Amita Datta‐Mannan; Arie Regev; David E. Coutant; Andrew J. Dropsey; Joanne Foster; Spencer Jones; Josh Poorbaugh; Carsten Schmitz; Evan Wang; Michael E. Woodman

Title: Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshop

Journal: Clinical and Translational Science

Publication Date: April 2024

DOI: 10.1111/cts.13785

Contributors: Jing Liu; Karen Rowland‐Yeo; Almut Winterstein; Simon Dagenais; Qi Liu; Jeffrey S. Barrett; Rui Zhu; Cyrus Ghobadi; Amita Datta‐Mannan; Joy Hsu et al.

Title: Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals

Journal: PLOS ONE

Publication Date: April 17, 2024

DOI: 10.1371/journal.pone.0293703

Contributors: Amita Datta-Mannan; Satish Rojekar; Hiuwan Choi; Zhaoyan Jin; Ling Liu; Jirong Lu; David J. Stokell; Anthony T. Murphy; Kenneth W. Dunn; Michelle M. Martinez et al.

Title: Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

Journal: Clinical Pharmacology & Therapeutics

Publication Date: March 27, 2024

DOI: 10.1002/cpt.3242

Contributors: Mohamed‐Eslam F. Mohamed; Sandhya Girish; Rita Humeniuk; Silpa Nuthalapati; Amit Desai; Amita Datta‐Mannan; Ferdous Gheyas; Jitendra Kanodia; Sravanthi Cheeti; Tong Zhu

Tony Shindano | Gastroenterology Award | Best Researcher Award

Posted on by ScienceFather

Prof. Tony Shindano | Gastroenterology Award | Best Researcher Award

Prof. Tony Shindano, Catholic University of Bukavu, Congo

👨‍⚕️ Dr. Tony Shindano Akilimali is a seasoned Consultant Gastroenterologist and Professor at the University of Bukavu, with 19 years of experience in the medical field. He holds a PhD and Master’s in Internal Medicine, specializing in Gastroenterology. Dr. Shindano is renowned for his expertise in gastrointestinal endoscopic explorations and managing common GI disorders. He has published extensively on hepatitis and viral infections, receiving accolades such as the Young Central Africa Investigator Award. Beyond medicine, he enjoys reading, music, and mentoring. Fluent in French, English, Swahili, and Lingala, Dr. Shindano is dedicated to advancing healthcare in the Democratic Republic of Congo. 🏥📚🌍

Publication Profile

Google Scholar

Educational Background 

📚 Dr. Tony Shindano Akilimali’s educational journey commenced at the Imara Institute, where he obtained his primary and secondary education certificates. He then pursued his passion for medicine, earning his medical degree from the Catholic University of Bukavu in 2004. Dr. Shindano’s academic pursuit continued with an internship in Internal Medicine and Gastroenterology at the Université Catholique de Louvain from 2005 to 2007. Later, he furthered his expertise by completing a Master’s in Internal Medicine at the University of Kinshasa from 2007 to 2011. His academic pinnacle was achieved with a Doctoral Thesis in Medicine from the Université Catholique de Louvain between 2013 and 2017. 🏥🎓

 

Academic Qualification 

🎓 Dr. Tony Shindano Akilimali’s academic and professional qualifications reflect his dedication to advancing medical knowledge and expertise. He holds a PhD from the Université Catholique de Louvain, accompanied by a Certificate in Medical Science Research from the same institution. His journey also includes a Master of Medicine in Internal Medicine from the University of Kinshasa and specialized training in Gastroenterology from Université Catholique de Louvain. Dr. Shindano further honed his skills through an Advanced Endoscopy Training Course in Italy and international post-graduate training in hepato-gastroenterology in Morocco. His foundational medical degree was obtained from the Catholic University of Bukavu, solidifying his commitment to healthcare excellence. 🏥📚

 

Work Experience

👨‍⚕️ Dr. Tony Shindano Akilimali’s professional journey spans nearly two decades, marked by significant roles in healthcare and academia. Since 2022, he has served as a Full Professor at the Faculty of Medicine at the University of Bukavu (UCB), contributing extensively to medical education. Notably, in 2020, amidst the COVID-19 pandemic, he led as President of the scientific sub-commission for the South Kivu committee’s response against COVID-19. Prior to his professorship, he held positions as Assistant Professor and Lecturer at UCB, while simultaneously practicing as a Specialist in Hepato-Gastroenterology and Internal Medicine. Dr. Shindano’s leadership extends to administrative roles, including Deputy Medical Director and President of the local medical board. His diverse experience reflects his commitment to healthcare excellence and education. 🏥📚

Awards and Honors 

🏆 Dr. Tony Shindano Akilimali’s dedication and contributions to the field of medicine were recognized with the prestigious Young Central Africa Investigator Award. He received this honor at the 14th “Journées de Gastro-Entérologie d’Afrique Francophone” in 2011, held in Brazzaville, Republic of Congo. This accolade highlights Dr. Shindano’s exceptional work and commitment to advancing gastroenterology research and healthcare in Central Africa. The award underscores his significant impact as a researcher and clinician, setting a standard for excellence and innovation in his field. 🌍👨‍⚕️

 

Research Focus

🔬 Dr. Tony Shindano Akilimali’s research focus primarily centers around viral hepatitis, particularly hepatitis B and C, as well as their co-infections with HIV. His extensive body of work includes systematic reviews, case reports, and studies exploring the prevalence, risk factors, and management strategies for these infectious diseases in the Democratic Republic of Congo. Additionally, Dr. Shindano has contributed to understanding the impact of antiretroviral therapy on lipid profiles in HIV patients and investigating the efficacy of Helicobacter pylori eradication regimes. Through his research, he aims to advance knowledge and improve healthcare outcomes in his region. 🦠🔍

 

Publication Top Notes 

Occult HBV reactivation induced by ibrutinib treatment: a case report – Cited by 47 – 2015 📖
📄Knowledge, attitudes, and practices of health-care workers about viral hepatitis B and C in south Kivu– Cited by 33 – 2017 📖
📄 Hepatitis B, hepatitis C and HIV in pregnant women in the community in the Democratic Republic of Congo – Cited by 28 – 2015 📖
📄 Hepatitis B virus infection in the Democratic Republic of Congo: a systematic review of prevalence studies (2000–2016) – Cited by 16 – 2018 📖
📄 Foetal ‘flat’bile acids reappear during human liver regeneration after surgery – Cited by 13 – 2009 📖
📄 Hepatitis C virus in sub-Saharan Africa: a long road to elimination – Cited by 10 – 2021 📖
📄 Genetic and phylogenic characterization of hepatitis B virus in the eastern part of the Democratic Republic of Congo – Cited by 7 – 2018 📖
📄 Nifuroxazide-induced acute pancreatitis: a new side-effect for an old drug? – Cited by 7 – 2007 📖
📄 Hepatitis B, Hepatitis C and HIV among Children 6 to 59 Months in the Community in the Democratic Republic of Congo – Cited by 5 – 2015 📖
📄 Changes of lipid profile and other biological parameters in people living with human immunodeficiency virus on highly active antiretroviral therapy in the General Referral … – Cited by 3 – 2020 📖